AKBA profile · all as-reported value updates
Akebia Therapeutics, Inc. (AKBA) as-reported value updates
Descriptive filing record — not investment advice. This page compares two SEC XBRL-filed values for the same fiscal period. It does not state why the values differ and is not a rating, score, or recommendation. See Disclaimer.
Reported values for the same fiscal period can differ between filings for many routine reasons: re-presentation for discontinued operations, adoption of new accounting standards, reclassifications, changes in rounding precision, and amendments. This ledger records that the filed values differ; it does not and cannot determine why. Both filings are linked below so the reader can consult the source.
Ledger table figure
| Metric | FY | Earliest XBRL-filed value | Currently on file | Difference | Difference % | Label | Filing links | Notes |
|---|---|---|---|---|---|---|---|---|
| Stockholders' equity | 2022 | 9,342,000 | 5,230,000 | -4,112,000 | -44.02% | figure amended in 10-K/A | 0001628280-23-007539 0001517022-26-000020 | 5 filed observations examined for this concept and period. |
| Net income | 2017 | -76,914,000 | -73,671,000 | 3,243,000 | +4.22% | revised comparative figure | 0001564590-18-005286 0001564590-20-010491 | 3 filed observations examined for this concept and period. |
| Operating income | 2017 | -79,917,000 | -76,674,000 | 3,243,000 | +4.06% | revised comparative figure | 0001564590-18-005286 0001564590-20-010491 | 3 filed observations examined for this concept and period. |
| Stockholders' equity | 2021 | 76,456,000 | 74,008,000 | -2,448,000 | -3.20% | figure amended in 10-K/A | 0001628280-22-004522 0001628280-24-011270 | 4 filed observations examined for this concept and period. |
| Stockholders' equity | 2017 | 119,331,000 | 122,574,000 | 3,243,000 | +2.65% | revised comparative figure | 0001564590-18-005286 0001628280-21-003283 | 4 filed observations examined for this concept and period. |
| Liabilities | 2022 | 342,488,000 | 350,824,000 | 8,336,000 | +2.38% | figure amended in 10-K/A | 0001628280-23-007539 0001628280-24-011270 | 3 filed observations examined for this concept and period. |
| Operating income | 2022 | -79,115,000 | -80,779,000 | -1,664,000 | -2.06% | figure amended in 10-K/A | 0001628280-23-007539 0001628280-24-011270 | 3 filed observations examined for this concept and period. |
| Net income | 2022 | -92,562,000 | -94,226,000 | -1,664,000 | -1.77% | figure amended in 10-K/A | 0001628280-23-007539 0001628280-24-011270 | 3 filed observations examined for this concept and period. |
| Liabilities | 2021 | 449,094,000 | 455,339,000 | 6,245,000 | +1.37% | figure amended in 10-K/A | 0001628280-22-004522 0001628280-23-030697 | 3 filed observations examined for this concept and period. |
| Liabilities | 2017 | 244,916,000 | 241,673,000 | -3,243,000 | -1.32% | revised comparative figure | 0001564590-18-005286 0001564590-19-009340 | 2 filed observations examined for this concept and period. |
| Stockholders' equity | 2020 | 247,618,000 | 244,354,000 | -3,264,000 | -1.32% | figure amended in 10-K/A | 0001628280-21-003283 0001628280-23-030697 | 4 filed observations examined for this concept and period. |
| Assets | 2022 | 351,830,000 | 356,054,000 | 4,224,000 | +1.19% | figure amended in 10-K/A | 0001628280-23-007539 0001628280-24-011270 | 3 filed observations examined for this concept and period. |